BDP1 Inhibitors

BDP1 Inhibitors, in the context of protein tyrosine phosphatase non-receptor type 18 (PTPN18), would constitute a diverse class of chemicals that inhibit the enzymatic activity of PTPN18. These inhibitors can operate through direct interaction with the active site, by mimicking the transition state of the substrate, or through non-competitive mechanisms that affect the protein's function. The first mechanism involves compounds that can either mimic the phosphate group that is normally removed by the phosphatase activity or bind to the active site and block access to the substrate. Sodium orthovanadate and deoxynojirimycin derivatives work in this manner, acting as competitive inhibitors. Phenylarsine oxide, by contrast, forms a bond with the catalytic cysteine residue, thus inactivating the enzyme.

On the other hand, some inhibitors interact with PTPN18 in a non-competitive manner, binding to sites other than the active site and inducing conformational changes that reduce the enzyme's activity. BVT-948 and trodusquemine are examples of such inhibitors. Additionally, there are compounds like zinc ionophores which elevate intracellular zinc levels, a known inhibitor of PTPs, thereby creating an inhibitory environment for PTPN18. Suramin's broad mechanism of inhibiting protein interactions can also interfere with PTPN18's function by preventing it from interacting with its substrates or regulatory proteins.